Jonas Jendi

TrackPaw Scientifics deep tech solution for 24/7 monitoring of early stage pharmaceutical development offers improved animal welfare together with better study outcomes.

Gesynta Pharmas drug candidate vipoglanstat (GS-248) is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life, and current drug treatments are inadequate for many patients. Gesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy. Gesynta Pharma’s second drug candidate to reach clinical development, GS-073, has the same mode of action as vipoglanstat. GS-073 is ready to enter clinical phase I for the treatment of chronic inflammatory pain. Gesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.

Elypta is a Swedish molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome – system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer noninvasively. Elypta is advancing a broad clinical program across different cancers with the first indication expected to be early detection of recurrence in renal cell carcinoma. Several years of research in Nielsen lab at Chalmers University of Technology in Gothenburg, Sweden led to the founding of Elypta in May 2017 by Francesco Gatto and Jens Nielsen.

Airsonett is a Swedish medical device company that leads the way in the development of non-pharmaceutical treatment of allergic asthma and eczema. We do this by providing Airsonett AIR4, a safe and effective home treatment device that improve health-related quality of life. Main owners are Industrifonden, SEB Venture Capital, Magnus Lundberg and Fåhraeus Startup & Growth. Airsonett has an impressive patent portfolio and has invested heavily in clinical research and product development. Air4 creates a sleep zone that protects you from the exposure to allergens and particles that occur at night and we believe that everyone deserves to breathe perfectly clean air while they sleep. Air4 was initially created for people with severe atopic asthma who, in spite of taking asthma medication, still has poorly controlled asthma. Air4 is recommended by healthcare professionals as an effective at-home treatment for allergic asthma and other allergy induced diseases such as rhinitis and eczema. Using Air4 has no pharmacological side effects and is suitable for both adults and children.

AVIDICARE AB Avidicare AB is a research based medtech company with a unique technology for management of airborne bacteria and virus contamination in hospitals. Opragon® is the company’s major product and Opragon is a complete product line for reduction of airborne bacterial contamination in hospitals, primarily for infection sensitive surgery. Ensuring ultra-clean air in the whole operating room, Opragon also provides optimal working conditions for the operating team while saving energy. Its state-of-the art design enables flexible installations and shows how we help healthcare providers work Towards Zero Infections.

TrackPaw Scientifics deep tech solution for 24/7 monitoring of early stage pharmaceutical development offers improved animal welfare together with better study outcomes.

Gesynta Pharmas drug candidate vipoglanstat (GS-248) is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life, and current drug treatments are inadequate for many patients. Gesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy. Gesynta Pharma’s second drug candidate to reach clinical development, GS-073, has the same mode of action as vipoglanstat. GS-073 is ready to enter clinical phase I for the treatment of chronic inflammatory pain. Gesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.

Sweden’s Venture Capital Fund. We look for unique, scalable innovations that improve our society through breakthrough technologies and science. Industrifonden invest in early-stage companies, from seed to A-round funding, and sometimes earlier. Our first ticket is often 10-50 million SEK, with the capacity to invest considerably more during the lifecycle. Our fund has an evergreen structure allowing us to focus less on short-term wins and focus more on investments that will create long-term value.

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.

Elypta is a Swedish molecular diagnostics company focused on reducing cancer mortality through early detection. Elypta is pioneering a metabolism-based liquid biopsy and measures the GAGome – system biomarkers of tumor metabolism. Machine learning algorithms are then used to detect signatures of cancer noninvasively. Elypta is advancing a broad clinical program across different cancers with the first indication expected to be early detection of recurrence in renal cell carcinoma. Several years of research in Nielsen lab at Chalmers University of Technology in Gothenburg, Sweden led to the founding of Elypta in May 2017 by Francesco Gatto and Jens Nielsen.